Neutropenia Treatment

Neutropenia: When a Low Neutrophil Count Becomes a Medical Priority

Neutropenia means the number of neutrophils in your blood is lower than normal. Neutrophils are a type of white blood cell and one of the body’s first defences against bacteria and certain fungal infections, so a significant fall in their number makes infection more likely, faster moving and sometimes harder to detect in its early stages. Neutropenia is not a single disease. It is a laboratory finding with many possible causes, and the right response depends on which cause is behind it.

Learning that you or someone you love has neutropenia can be unsettling, especially when the result appears unexpectedly on a routine blood test or during cancer treatment. The most immediate concerns are usually practical ones: How serious is this? Can I travel? Do I need hospital care? Is this related to chemotherapy, an immune condition, a medication, or something in the bone marrow? These are the right questions to ask. Some forms of neutropenia are mild and temporary and need nothing more than a repeat blood test. Others require urgent treatment, close monitoring, or a coordinated plan involving haematology, oncology, infectious diseases, rheumatology or paediatrics.

The seriousness of neutropenia depends on more than the number itself. Infection risk is shaped by how low the count is, how quickly it fell, how long it stays low, whether fever or other symptoms are present, and whether you have other medical conditions. A fever in a person with severe neutropenia is treated as a medical urgency, because a depleted immune system may not produce the usual warning signs of infection. In that setting, early evaluation and timely antibiotics can be critical.

At the same time, good neutropenia care is not only about reacting to infection. A well-built treatment plan also works to identify the cause, reduce preventable risks, review medications that may be contributing, support bone marrow recovery and help you live as normally and safely as possible. For patients whose care crosses borders or healthcare systems, it also means a pathway that can be understood clearly at every step, with prior records reviewed carefully rather than assumed.

Why are my neutrophils low?

A low neutrophil count usually has one of three broad explanations: the bone marrow is producing fewer neutrophils than normal, neutrophils are being destroyed or consumed faster than they can be replaced, or neutrophils are shifting out of the circulating blood and into the tissues. Reduced production is seen with chemotherapy, some medications, nutritional deficiencies and bone marrow disorders. Increased destruction occurs in autoimmune conditions and some severe infections. Each neutrophil is short-lived — circulating for hours rather than weeks — so the count can change quickly in either direction, which is why doctors often look at the trend over several tests rather than a single result. The sections below explain the full range of causes and what evaluation involves.

What Neutropenia Treatment Involves

Neutropenia treatment is the medical approach used to manage a low neutrophil count: preventing infection where possible, treating infection promptly when it occurs, and addressing the underlying cause whenever one can be found. The plan is individualised, because neutropenia can result from very different situations — chemotherapy, targeted cancer therapies, autoimmune disease, viral infections, nutritional deficiencies, inherited conditions, medication effects, bone marrow disorders or severe systemic illness — and the right treatment for one cause may be entirely wrong for another.

The first step is always the same: establish how low the count actually is and whether symptoms are present. Mild neutropenia in a well person may need nothing more than observation and repeat blood testing. Moderate or severe neutropenia calls for a more detailed evaluation. If fever is present — particularly in a patient receiving chemotherapy or with a severely reduced count — treatment often begins immediately, while diagnostic tests are still underway. Waiting for complete answers before acting is not how febrile neutropenia is managed anywhere that manages it well.

How do doctors treat neutropenia?

Doctors treat neutropenia by combining infection control with treatment of the underlying cause: antibiotics when bacterial infection is suspected or confirmed, antifungal or antiviral medicines in selected cases, growth-factor injections that stimulate the bone marrow to produce neutrophils, changes to cancer treatment schedules, replacement of a vitamin or mineral when a deficiency is found, and therapy directed at an autoimmune or bone marrow condition where one is identified. When a medication is the likely trigger, the treating doctor decides whether it should be stopped, replaced or adjusted — a decision that has to weigh the condition the medication was treating in the first place. In some patients treatment is short-term and the count recovers within weeks. In others, neutropenia becomes a condition that needs long-term monitoring and preventive strategies rather than continuous intervention.

How do I fix my neutropenia?

You cannot fix neutropenia yourself, because the correct treatment depends entirely on the cause — and the cause can only be established by proper evaluation. There is no supplement, diet or routine that reliably raises a neutrophil count across the board. What you can genuinely influence is risk: careful hand hygiene, good oral care, protecting the skin from cuts, following food-safety guidance when the count is severely low, attending scheduled blood tests, and giving your doctors a complete and honest list of every medication and supplement you take, since some over-the-counter and herbal products can affect blood counts. Any change to a prescribed medication belongs to your treating doctor, not to guesswork.

Good neutropenia care is structured but flexible. It uses evidence-based protocols for urgent situations such as febrile neutropenia, while leaving room for physicians to tailor the plan to your diagnosis, infection history, age, travel needs, cancer treatment goals, organ function and preferences. The central aim is to protect you during periods of immune vulnerability without imposing medications or restrictions that the actual risk does not justify.

Who Needs Evaluation, and How Neutropenia Is Diagnosed

Evaluation is warranted when routine blood tests show a low neutrophil count, when infections occur repeatedly or behave unusually, or when a fever develops during a known period of low immunity. Some people feel completely well and discover neutropenia incidentally. Others have symptoms that prompted the test in the first place: fever, chills, mouth ulcers, sore throat, gum inflammation, skin infections, sinus infections, pneumonia, painful urination, or persistent fatigue linked to an underlying condition. Both situations deserve a proper explanation, even if the pace of the work-up differs.

What is considered neutropenia?

Neutropenia is defined by the count of absolute neutrophils — reported on your blood test as the ANC, or absolute neutrophil count — rather than by the total white blood cell figure. In adults, an ANC below about 1,500 cells per microlitre of blood is generally considered neutropenia. Counts between roughly 1,000 and 1,500 are described as mild, between 500 and 1,000 as moderate, and below 500 as severe, which is where infection risk rises most sharply. These thresholds are working definitions rather than rigid lines: normal ranges differ by age in children, and some entirely healthy people — particularly those of African or Middle Eastern ancestry — have a naturally lower baseline without any increase in infection risk, a pattern known as benign ethnic neutropenia. This is one reason a single low result is interpreted in context, alongside your history and previous counts, rather than in isolation.

What are agranulocytosis and leukopenia?

Leukopenia means the total white blood cell count is low, while agranulocytosis means neutrophils are almost completely absent — typically an ANC below about 200 cells per microlitre. The terms overlap with neutropenia but are not interchangeable. Leukopenia is the broader finding, since white blood cells include lymphocytes and other cell types besides neutrophils; a person can have leukopenia without meaningful neutropenia, and vice versa. Agranulocytosis sits at the severe end of the spectrum, is often triggered by a medication reaction, and is treated as an emergency because the body has essentially no neutrophil defence while it lasts.

Diagnosis begins with a complete blood count and differential, which measures the types and numbers of white blood cells. Physicians also check whether other blood cell lines are affected. If neutropenia occurs together with anaemia or low platelets, the diagnostic focus shifts towards bone marrow production problems, medication toxicity, autoimmune disease, infection or haematological disorders, because a problem across several cell lines points to a different set of causes than an isolated low neutrophil count.

The medical history carries particular weight. Doctors ask about recent chemotherapy, radiation therapy, immunotherapy, targeted therapy, antibiotics, anticonvulsants, antithyroid drugs, psychiatric medications and herbal supplements; about recent viral illnesses, autoimmune symptoms, weight loss, night sweats and enlarged lymph nodes; and about family history and past infections. For patients who have received care in more than one country, physicians also review vaccination history, travel exposures, prior hospitalisations and previous antibiotic use, because resistant organisms and region-specific exposures can change treatment decisions.

Further testing is chosen to fit the picture rather than ordered wholesale. It may include repeat blood counts to establish a trend, review of a peripheral blood smear by a specialist, inflammatory markers, blood cultures if fever is present, viral testing, nutritional testing for vitamin B12, folate or copper deficiency, immune studies, autoimmune markers, imaging when infection is suspected, and bone marrow aspiration or biopsy when marrow disease is a genuine concern. In children or young adults with long-standing neutropenia, genetic testing may be considered if a congenital or inherited form is suspected.

Patients receiving cancer treatment are among the most common groups needing active neutropenia management. Chemotherapy can temporarily suppress the bone marrow, and some regimens carry a recognised higher risk of febrile neutropenia. In these cases the oncology team acts before the count becomes dangerous: scheduled blood count monitoring, dose-timing adjustments, infection-prevention counselling and growth-factor injections when medically indicated.

Other patients need care because neutropenia is chronic or recurrent rather than acute. Chronic benign neutropenia, autoimmune neutropenia, cyclic neutropenia and neutropenia associated with rheumatological disease usually call for a different type of plan — one built around monitoring, clear instructions for responding to infection, and selective use of medications, rather than continuous intensive treatment.

What Causes Neutropenia?

Neutropenia has many causes, and identifying the right one is the foundation of every sound treatment decision. Broadly, the causes fall into six groups: cancer treatment, bone marrow disorders, autoimmune disease, infection, nutritional or medication effects, and childhood-specific conditions. Treatment addresses both the low count itself and whichever of these is driving it.

What is the most common cause of neutropenia?

In hospital and cancer-care settings, chemotherapy and other medications are the most common causes of clinically significant neutropenia; in the wider population, transient viral infections are among the most frequent triggers, particularly in children. Which cause is “most common” therefore depends on where you look. For a patient mid-way through a chemotherapy course, treatment suppression is by far the likeliest explanation. For an otherwise healthy person with a mildly low count after a flu-like illness, a passing viral effect is the more probable answer — and a repeat test a few weeks later often settles the question.

Chemotherapy and cancer-related neutropenia

In cancer care, treatment commonly focuses on chemotherapy-induced neutropenia, febrile neutropenia and neutropenia caused by cancer involving the bone marrow itself. The goal is twofold: keep the patient safe through the vulnerable window, and protect the overall cancer treatment plan wherever possible, since unnecessary interruptions to treatment carry their own cost.

Bone marrow disorders

In haematology, neutropenia may signal a bone marrow disorder such as aplastic anaemia, myelodysplastic syndromes, leukaemia, lymphoma or marrow infiltration by another disease. These conditions require a more extensive diagnostic pathway and may involve treatment well beyond infection prevention — disease-specific therapies, transfusion support, immunosuppressive treatment, or stem cell transplantation in selected cases.

Autoimmune and rheumatological causes

Neutropenia can accompany autoimmune disorders including systemic lupus erythematosus, rheumatoid arthritis and Felty syndrome, where the immune system destroys neutrophils directly. Treatment here involves a careful balancing act: controlling the immune disease, managing infection risk, and working out whether the immune-modifying medications a patient already takes are helping the situation or contributing to it.

Infections

Viral illnesses, severe bacterial infection, HIV, hepatitis, tuberculosis and other systemic infections can all lower the neutrophil count. Some infections suppress bone marrow activity directly; others trigger immune changes that pull neutrophils out of circulation. Evaluation considers both the infection and the patient’s underlying immune status, since each affects how the other is treated.

Nutritional deficiencies and medication reactions

These causes matter because they are often reversible. Deficiencies in vitamin B12, folate or copper can suppress blood cell production, and correcting the deficiency may allow the count to recover. Certain medications suppress neutrophils in rare but serious ways — the mechanism behind many cases of agranulocytosis. Identifying a drug or deficiency as the culprit can change the entire course of care, sometimes replacing a long diagnostic pathway with a straightforward correction under medical supervision.

Neutropenia in children

Children may need treatment for neonatal neutropenia, autoimmune neutropenia of childhood, congenital neutropenia syndromes, or recurrent infection patterns that prompt immune evaluation. Paediatric neutropenia requires age-specific interpretation of blood counts — what is low for an adult may be normal for an infant — and a careful balance between protection and avoiding restrictions that interfere with normal development for no real safety gain.

How Neutropenia Treatment Is Performed

Treatment begins with risk assessment. The medical team weighs the absolute neutrophil count, temperature, symptoms, recent treatments, organ function, infection history and overall clinical stability. This assessment determines the setting of care: some patients can be managed as outpatients with close follow-up, while others are safer admitted to hospital. Neither option is automatically better; the right choice depends on the risk profile of the individual patient.

What happens when a neutropenic patient develops fever?

Fever in a neutropenic patient is treated as a medical urgency, and evaluation and treatment run in parallel rather than in sequence. A typical pathway looks like this:

• Rapid assessment. Vital signs, symptom review and an urgent blood count establish how severe the situation is.
• Cultures. Blood cultures are taken from a vein and from any central venous catheter if one is present.
• Targeted tests. Urine tests, chest imaging, respiratory viral tests or wound cultures may be added depending on symptoms.
• Prompt antibiotics. Broad-spectrum antibiotics are commonly started quickly, without waiting for every result, because infection can progress rapidly when neutrophil defences are low.
• Monitoring and adjustment. As culture results and the clinical course become clear, treatment is narrowed, broadened or extended accordingly.

For patients without fever, preparation focuses on understanding the cause. The physician reviews every medication and all previous blood counts to determine whether neutropenia is new, worsening, chronic or cyclical. Cancer patients typically have counts checked at scheduled intervals before each treatment cycle. Patients with chronic neutropenia may need serial counts over several weeks to reveal a pattern — cyclic neutropenia, for example, only shows itself when counts are tracked over time.

Medication choices are guided by international protocols, local resistance patterns, allergy history, kidney and liver function, and previous culture results. Antifungal or antiviral medicines are added when the clinical situation genuinely suggests those risks — most often in prolonged severe neutropenia, after stem cell transplantation, in haematological malignancies, or when specific symptoms point that way. They are not routine additions for every low count.

When are growth-factor injections used?

Growth-factor injections stimulate the bone marrow to produce and release neutrophils, and they are used selectively rather than universally. They are commonly considered in chemotherapy-associated neutropenia when the risk of febrile neutropenia is significant, when a previous treatment cycle caused serious neutropenia, or when keeping the cancer treatment on schedule is medically important. They may also have a role in certain chronic neutropenia syndromes. They are not necessary for every patient with a low neutrophil count — a mildly neutropenic patient with no infections gains little from them — so the decision is individualised each time.

When neutropenia is traced to a medication, the treating doctor may stop, replace or adjust the suspected drug. This step is taken deliberately, especially when the medication is important for another condition; the risks on both sides have to be weighed by someone who can see the whole clinical picture. When a deficiency is identified, vitamin or mineral replacement is prescribed. When autoimmune neutropenia is suspected, the plan may involve monitoring alone, immune-directed therapy or growth factors, calibrated to how often and how seriously the patient actually gets infections rather than to the number alone.

When a bone marrow disorder is suspected, bone marrow aspiration and biopsy provide the definitive answer. The procedure is typically performed with local anaesthesia and, when appropriate, sedation. A small sample of marrow is collected — usually from the back of the pelvic bone — and examined using microscopy, flow cytometry, cytogenetics, molecular tests and other laboratory methods. Together these show whether the marrow is producing neutrophils normally, whether abnormal cells are present, and whether a specific haematological diagnosis is driving the low count.

Modern neutropenia care uses several layers of technology, each serving precision rather than spectacle. Automated haematology analysers measure blood cell counts quickly and accurately. Peripheral smear examination lets specialists assess cell appearance directly. Microbiology laboratories identify bacteria, fungi and viruses and test which medications are likely to work against them. Imaging — ultrasound, X-ray, computed tomography or magnetic resonance imaging — can locate hidden sources of infection. In complex cases, molecular and genetic testing clarifies inherited conditions, marrow disorders or cancer-related findings.

How long treatment lasts varies widely. A single episode of chemotherapy-related neutropenia may improve within days to a couple of weeks, depending on the regimen and whether growth factors are used. Febrile neutropenia may require hospital treatment until the patient is clinically stable, cultures have been assessed, and neutrophil recovery is underway or a safe outpatient plan exists. Chronic neutropenia may need follow-up over months or years, with treatment intensity adjusted to the infection history rather than the laboratory number alone.

Recovery combines medical monitoring with practical daily precautions. Care teams typically ask patients to report fever without delay, practise careful hand hygiene, avoid close contact with people who are actively ill, maintain good oral care, protect the skin from cuts, and follow food-safety guidance while neutropenia is severe. The plan should stay realistic. The goal is not to isolate every patient behind unnecessary rules, but to match precautions to the actual level of risk — and to relax them as the count recovers.

Why Acting Early Matters

Early action matters because neutropenia changes how infections behave. A person with a normal neutrophil count usually develops redness, swelling, pus or strong inflammatory symptoms at the site of an infection. A person with severe neutropenia may show few of those local signs, and fever may be the only early warning. That is why fever during neutropenia is taken seriously even when the patient otherwise feels relatively well — the absence of dramatic symptoms is not reassurance; it may simply be the absence of neutrophils to produce them.

Delayed evaluation gives infection time to spread into the bloodstream or deeper tissues. In high-risk patients — those receiving intensive chemotherapy, living with haematological cancers, or recovering from stem cell transplantation — the window for straightforward treatment can be short. Prompt antibiotics, cultures and clinical monitoring reduce the chance that a manageable infection becomes a serious complication.

Acting early also matters when nothing is urgent. Repeatedly low counts should not be filed away and forgotten, particularly if they are worsening, persistent or accompanied by other abnormal blood results. Identifying a medication effect, nutritional deficiency, immune disease or marrow disorder earlier allows treatment before infections occur — or before the underlying condition advances quietly.

For patients whose treatment involves international travel, early planning has particular value. When neutropenia is known or suspected, a treating team can advise whether travel is appropriate at all, what records will be needed at the destination, whether precautions are required during the journey, and whether assessment should happen before departure rather than after arrival.

Benefits of Neutropenia Treatment

The benefits of treatment depend on the cause and severity of neutropenia, but the central aims are consistent: reduce infection risk, treat infections promptly when they occur, and support recovery of the immune system.

Benefit	What It Means for You
Lower risk of serious infection	Preventive measures, monitoring and selected medications reduce the likelihood that a low neutrophil count leads to severe bacterial or fungal illness.
Faster response when fever occurs	A clear febrile neutropenia plan means clinicians can begin antibiotics and testing without unnecessary delay, and you know in advance what the plan is.
Identification of the underlying cause	Establishing whether neutropenia is related to chemotherapy, medication, deficiency, immune disease, infection or bone marrow disease allows precise rather than generic treatment.
Support for ongoing cancer treatment	In selected patients, growth factors and careful scheduling reduce treatment interruptions while maintaining safety.
More confident daily living	Personalised guidance clarifies realistic precautions, warning signs, travel considerations and when normal activities can safely continue.

Recovery Timeline After Neutropenia Treatment

Recovery follows the cause. The severity of the neutrophil decrease and the presence or absence of infection shape the pace, but many patients move through a broadly similar pattern of monitoring and gradual risk reduction.

Time Period	What Patients Can Expect
Day 1	Assessment includes blood tests, symptom review, medication review, and cultures or imaging if infection is suspected. If fever is present with significant neutropenia, antibiotics may be started urgently.
First Week	Blood counts are repeated to follow the neutrophil trend. Depending on cause and risk level, care may include antibiotics, growth-factor injections, medication changes or supportive treatment.
First Month	Many temporary causes begin to improve — particularly after recovery from chemotherapy suppression, viral illness or medication adjustment. Neutropenia that persists prompts further testing.
Longer Term	Chronic, autoimmune, inherited or marrow-related neutropenia usually means periodic follow-up, an individualised infection plan, and treatment directed at the underlying condition.

What Influences Outcomes and What Counts as a Good Result

Several interconnected factors shape the outcome of neutropenia treatment. Depth matters: very low counts carry higher infection risk than mild reductions. Duration matters too — a brief dip after a chemotherapy cycle is a different clinical problem from neutropenia that lasts for weeks or recurs on a cycle. And the presence of fever or active infection is one of the most important factors of all, because treatment timing influences how an infection unfolds.

Other health conditions add weight to the equation. Kidney disease, liver disease, diabetes, lung disease, malnutrition or recent surgery can each increase risk and constrain medication choices, which is why the same neutrophil count can mean quite different plans for two different patients.

What is the prognosis for neutropenia?

The prognosis for neutropenia depends almost entirely on its cause, its depth and how long it lasts. Medication-related neutropenia often improves after the causative drug is withdrawn by the treating doctor, though close monitoring is needed while the count recovers. Nutritional deficiencies can respond well to replacement therapy once correctly diagnosed. Chemotherapy-related neutropenia usually follows a predictable pattern of fall and recovery, though the risk varies with cancer type, regimen, dose intensity, age, prior treatment and marrow reserve. Bone marrow disorders sit at the more complex end, where the outlook belongs to the underlying disease and its specific therapy rather than to the neutrophil count itself. Chronic benign forms, by contrast, are compatible with decades of ordinary life. No honest page can give you a single prognosis for a finding this varied; what evaluation can give you is a prognosis for your cause.

A good result is not defined only by returning the count to a normal range, though that is often desirable. It also means preventing serious infections, treating any infections effectively, minimising unnecessary treatment delays, preserving quality of life, and leaving you with clear instructions for what to do if symptoms arise. In chronic neutropenia, some patients live well with lower-than-average counts, provided infections are rare and follow-up is in place.

Your own participation genuinely influences the outcome. Reporting fever promptly to your care team, taking medications as prescribed, attending follow-up blood tests, sharing a complete medication and supplement list, and following practical hygiene and food-safety guidance all make care safer. For patients arriving from other health systems, prior laboratory reports, chemotherapy protocols, pathology results, imaging, culture reports and discharge summaries let physicians make faster and more accurate decisions than starting from a blank page.

Coordination among specialists matters most in complex settings. Oncology, haematology, infectious diseases, intensive care, rheumatology, paediatrics, laboratory medicine and pharmacy may all contribute to a single patient’s plan. That collaboration keeps infection treatment, diagnostic evaluation and the management of the underlying disease aligned, rather than handled as separate problems by separate departments.

How Acibadem Approaches Neutropenia Care

Neutropenia care tends to be sought internationally when the situation is medically complex, when a second opinion is wanted, or when treatment has to be coordinated across several specialties at once. At Acibadem, neutropenia is evaluated within a hospital environment built to support both urgent decision-making and careful diagnostic work — a combination that matters for patients with cancer, haematological disease, recurrent infections, unexplained low blood counts, or treatment plans that need close monitoring.

Care is planned by the specialty the clinical picture actually calls for. Haematologists evaluate unexplained or persistent neutropenia, bone marrow disorders and chronic neutropenia syndromes. Medical oncologists manage chemotherapy-related neutropenia and decisions about cancer treatment timing. Infectious disease specialists advise on fever, culture results, antibiotic selection, resistant organisms and preventive treatment where it is genuinely indicated. Paediatric specialists take the lead for children, and other departments join when autoimmune, nutritional, renal, hepatic or intensive-care issues are part of the picture.

For patients with cancer or suspected marrow disease, multidisciplinary boards review diagnostic findings and treatment options together — pathology, imaging, laboratory results, treatment history and the patient’s own goals discussed in one coordinated setting. The point of this structure is a treatment plan that is medically sound and practical for the individual, rather than one focused on the neutrophil count in isolation.

The diagnostic pathway mirrors what this page has described: detailed blood testing, microbiology services, imaging where an infection source needs to be found, and bone marrow evaluation for selected patients. Advanced laboratory methods help distinguish temporary suppression from immune-mediated destruction, medication effects, inherited patterns and haematological disease — distinctions that matter because the right treatment for one cause of neutropenia may be very different from the right treatment for another.

For patients whose care crosses borders, practical support sits alongside the medicine: help gathering medical records, arranging appointments, preparing for travel, understanding the treatment plan, and communicating in the patient’s preferred language. When a patient travels for evaluation, prior records — recent full blood counts, medication lists, chemotherapy details, culture results, imaging and specialist notes — allow the receiving team to judge urgency accurately and plan the first assessment well.

Personalised planning is the constant thread. A patient receiving chemotherapy may need a plan that protects against infection while preserving the intent of cancer treatment. A patient with chronic neutropenia may need long-term monitoring and clear fever instructions rather than aggressive medication. A patient with a suspected bone marrow disorder may need a comprehensive diagnostic pathway and a frank discussion of disease-specific therapies. In each case the plan is shaped by cause, severity, risk level and the patient’s broader medical context — not by a template.

Moving Forward With Clarity and a Safe Plan

Neutropenia spans the full range from a temporary laboratory finding to a serious condition requiring urgent treatment. The most useful step is never to interpret the number alone, but to understand what it means in context: how low the neutrophil count is, how long it has been low, whether fever or infection is present, and which underlying condition may be responsible.

With careful evaluation, most patients can be given a clear explanation of their risk and a practical plan for treatment, monitoring and daily life. When antibiotics, growth factors, medication changes, nutritional support or disease-specific therapies are needed, they can be used in a targeted way. When observation is the appropriate answer, patients can be followed without unnecessary intervention — alert to warning signs, but not organising their lives around a laboratory value that may never cause them harm.

The measure of good neutropenia care is proportion: urgency where urgency is warranted, patience where it is not, and at every stage an honest account of what the number does and does not mean for the person behind it.